Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.63 |
| ▸ | MMP13 | P45452 | 13/20 | 0.60 |
| ▸ | MMP9 | P14780 | 10/20 | 0.60 |
| ▸ | MMP2 | P08253 | 5/20 | 0.60 |
| ▸ | MMP8 | P22894 | 5/20 | 0.60 |
| ▸ | MMP7 | P09237 | 2/20 | 0.57 |
| ▸ | MMP1 | P03956 | 9/20 | 0.56 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7396462 | 0.84 | ADAM17 (0.65) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL7358814 | 0.83 | ADAM17 (0.72) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL14245317 | 0.83 | ADAM17 (0.63) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL6506400 | 0.83 | ADAM17 (0.63) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL3848565 | 0.83 | ADAM17 (0.63) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL6261998 | 0.83 | ADAM17 (0.63) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL6506403 | 0.83 | CA1 (0.65) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL6407732 | 0.81 | CA12 (0.46) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL6261997 | 0.81 | ADAM17 (0.61) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL15274643 | 0.81 | ADAM17 (0.58) | ADAM17MMP13MMP9MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6825354-B2 | OSTEOPOROSIS; RHEUMATIC DISEASES | WYETH HOLDINGS CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
| EP-1440057-A1 | ALLENIC ARYL SULFONAMIDE HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | Wyeth Holdings Corporation (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1147080-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6753337-B2 | INHIBITORS OF TNF-ALPHA CONVERTING ENZYME; TREATMENT OF ARTHRITIS, INFLAMMATION, INFLAMMATORY BOWEL DISEASE ETC, | WYETH HOLDINGS CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003037852-A1 | ALLENIC ARYL SULFONAMIDE HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1252143-A1 | METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES | American Cyanamid Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| US-20020099035-A1 | Method for preparing alpha-sulfonyl hydroxamic acid derivatives | WYETH HOLDINGS CORPORATION | 2002-07-25 | — | — | US | disclosed |
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | AMERICAN CYANAMID COMPANY | 2002-07-04 | — | — | US | disclosed |
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6340691-B1 | TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001055112-A1 | METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP13 16/4885MMP9 3/4885 |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP13 16/4885MMP9 3/4885 |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | ADAM17 7/4885MMP13 12/4885MMP9 14/4885 |
| US-20020099035-A1 | Method for preparing alpha-sulfonyl hydroxamic acid derivatives | MMP25, ADAMTS5, MMP9 | ADAM17 4/4885MMP13 22/4885MMP9 3/4885 |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | MMP12, MMP1, SI | ADAM17 78/4885MMP13 11/4885MMP9 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.